** Shares of surgical factory operator Surgery Partners SGRY.O rise 3.8% to $23 after Q1 results
** Co's Q1 revenue rises 8.2% to $776 mln from a year-ago
** Adj. EBITDA up 6.6% to $103.9 mln
** CFO Dave Doherty says Q1 results increase confidence to reaffirm FY guidance, amid uncertainty
** Nine out of 12 analysts rate stock "buy" or higher, three "hold"; Median PT is $33 - LSEG
** With session moves, SGRY up 9.4% YTD vs a 3.9% decline in the Nasdaq .IXIC
(Reporting by Twesha Dikshit)
((Twesha.Dikshit@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.